Renova Pharms

Renova Therapeutics is a clinical-stage biotechnology company specializing in the development of gene therapies for congestive heart failure and other chronic metabolic diseases. The company's lead candidate, RT-100, is an investigational gene therapy that delivers the human adenylyl cyclase type 6 (AC6) gene directly to the heart to improve cardiac function, currently in Phase 3 development. Renova also utilizes its Paracrine Gene Therapy (PGT) platform to develop systemic treatments for conditions like type 2 diabetes through localized gene delivery of urocortin proteins. The company's pipeline aims to provide long-term therapeutic benefits for large patient populations with chronic conditions through one-time or infrequent administrations.